17:57 , Aug 31, 2018 |  BC Week In Review  |  Clinical News

Teva wins first FDA approval for generic EpiPen

FDA approved an ANDA from Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA) for the first generic version of EpiPen epinephrine auto-injector for the emergency treatment of allergic reactions including anaphylaxis. Mylan N.V. (NASDAQ:MYL) markets the...
23:54 , Feb 14, 2017 |  BC Extra  |  Politics & Policy

GPhA rebrands as Association for Accessible Medicines

The Generic Pharmaceutical Association said it changed its name to the Association for Accessible Medicines amid the organization's "national effort to contain the cost of prescription medicines." The group also said Jeff Watson, president of global...
20:20 , Jan 20, 2017 |  BC Week In Review  |  Company News

Cigna, Mylan, Impax sales and marketing update

Cigna dropped coverage of branded EpiPen and EpiPen Jr. from Mylan and branded Adrenaclick from Impax to treat severe acute allergic reactions, replacing the epinephrine auto-injectors with generics. Separately, CVS said it dropped the price...
01:09 , Dec 7, 2016 |  BC Extra  |  Politics & Policy

Vermont releases drug pricing report

In its first report since the passage of a new price transparency law, the Vermont Attorney General's office identified drugs with substantial increases in wholesale acquisition cost (WAC). The document named three branded therapies --...
07:00 , Oct 17, 2016 |  BC Week In Review  |  Company News

Mylan inflammation news

Mylan will pay $465 million to the U.S. Department of Justice and other government entities to “resolve questions” about the classification of Mylan’s EpiPen epinephrine auto-injector in the Medicaid Drug Rebate Program. The company...
07:00 , Oct 7, 2016 |  BC Extra  |  Company News

Mylan pays $465M in DOJ settlement

Mylan N.V. (NASDAQ:MYL) said it agreed to a $465 million settlement with the U.S. Department of Justice and other government entities that will "resolve questions that have been raised" about the classification of Mylan's EpiPen...
07:00 , Sep 20, 2016 |  BC Extra  |  Politics & Policy

Senators call for review of Medicaid rebate program

In a letter to HHS Inspector General Daniel Levinson, 14 U.S. Senate Republicans requested a review of CMS's oversight of the Medicaid Drug Rebate Program (MDRP), saying they are "concerned that the controls in place,...
07:00 , Sep 14, 2016 |  BC Extra  |  Politics & Policy

House Oversight Committee holding EpiPen hearing

The U.S. House Committee on Oversight and Government Reform scheduled a Sept. 21 hearing to discuss price increases for EpiPen from Mylan N.V. (NASDAQ:MYL). The company's CEO Heather Bresch is scheduled to testify, as is...
07:00 , Sep 12, 2016 |  BioCentury  |  Politics, Policy & Law

Executive power

Years of congressional gridlock have caused power in Washington to shift to the White House, making the levers of power less accessible to pharmaceutical industry lobbyists. While Congress will continue to mine outrage over drug...
07:00 , Sep 6, 2016 |  BC Extra  |  Politics & Policy

Saunders says Allergan will limit price increases

In a blog post, Allergan plc (NYSE:AGN) President and CEO Brent Saunders pledged to price the company's products "in a way that is commensurate with, or lower than, the value they create," and to limit...